1. Home
  2. WKHS vs INTS Comparison

WKHS vs INTS Comparison

Compare WKHS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Workhorse Group Inc.

WKHS

Workhorse Group Inc.

HOLD

Current Price

$3.44

Market Cap

33.7M

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$4.75

Market Cap

11.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WKHS
INTS
Founded
2007
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.7M
11.4M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
WKHS
INTS
Price
$3.44
$4.75
Analyst Decision
Hold
Buy
Analyst Count
1
3
Target Price
$21.00
$38.00
AVG Volume (30 Days)
95.0K
26.0K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
86.92
N/A
EPS
N/A
N/A
Revenue
$763,173.00
N/A
Revenue This Year
$89.23
N/A
Revenue Next Year
$28.84
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.22
52 Week High
$11.80
$8.06

Technical Indicators

Market Signals
Indicator
WKHS
INTS
Relative Strength Index (RSI) 56.43 55.25
Support Level $3.22 $4.50
Resistance Level $3.50 $5.00
Average True Range (ATR) 0.26 0.28
MACD 0.00 0.05
Stochastic Oscillator 66.40 62.43

Price Performance

Historical Comparison
WKHS
INTS

About WKHS Workhorse Group Inc.

Workhorse Group Inc is a technology company with a vision to pioneer the transition to zero-emission commercial vehicles. Its focus is to provide sustainable and cost-effective solutions to the commercial transportation sector. It designs and manufactures all-electric vehicles, including the technology that optimizes the way these vehicles operate. It's focused on a core competency of bringing electric delivery vehicle platforms to serve the last-mile delivery market. Its products are marketed under the Workhorse brand.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: